Insmed gains after ending $500M sales pact with Leerink

seekingalpha11-19

cagkansayin Shares of Insmed (NASDAQ:INSM) traded higher on Tuesday after the rare-disease drug developer terminated a sales agreement under which Leerink Partners was named an agent to sell shares of...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484921262?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2075111295/image_2075111295.jpg","is_english":true,"pubTime":"2024-11-19 23:39","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2484921262","market":"hk","top_or_hot":-1,"title":"Insmed gains after ending $500M sales pact with Leerink","media":"seekingalpha","content":"<div>\n<p>cagkansayin Shares of Insmed (NASDAQ:INSM) traded higher on Tuesday after the rare-disease drug developer terminated a sales agreement under which Leerink Partners was named an agent to sell shares of...</p>\n\n<a href=\"https://seekingalpha.com/news/4307278-insmed-gains-after-ending-500-m-sales-pact-leerinktock\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed gains after ending $500M sales pact with Leerink</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed gains after ending $500M sales pact with Leerink\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 23:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4307278-insmed-gains-after-ending-500-m-sales-pact-leerinktock><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>cagkansayin Shares of Insmed (NASDAQ:INSM) traded higher on Tuesday after the rare-disease drug developer terminated a sales agreement under which Leerink Partners was named an agent to sell shares of...</p>\n\n<a href=\"https://seekingalpha.com/news/4307278-insmed-gains-after-ending-500-m-sales-pact-leerinktock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"https://seekingalpha.com/news/4307278-insmed-gains-after-ending-500-m-sales-pact-leerinktock","article_id":"2484921262","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2075111295/image_2075111295.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484921262","pubTimestamp":1732030756,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"cagkansayin Shares of Insmed  traded higher on Tuesday after the rare-disease drug developer terminated a sales agreement under which Leerink Partners was named an agent to sell shares of its common stock worth up to $500M. The company ended the deal on Nov. 18, and the decision will take effect immediately, Bridgewater, New Jersey-based Insmed  announced in a regulatory filing on Monday.  The company added that there won’t be any penalties associated with the termination and noted that no shares of its common stock had been issued under the agreement since Sep. 30. Insmed  shares ended lower in February as the company announced the agreement under which Leerink was appointed as the agent to offer and sell its common stock, with a par value of $0.01 per share.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"Insmed在终止与Leerink的5亿美元销售协议后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":0.9},"content_text":"cagkansayin Shares of Insmed (NASDAQ:INSM) traded higher on Tuesday after the rare-disease drug developer terminated a sales agreement under which Leerink Partners was named an agent to sell shares of its common stock worth up to $500M. The company ended the deal on Nov. 18, and the decision will take effect immediately, Bridgewater, New Jersey-based Insmed (NASDAQ:INSM) announced in a regulatory filing on Monday.  The company added that there won’t be any penalties associated with the termination and noted that no shares of its common stock had been issued under the agreement since Sep. 30. Insmed (INSM) shares ended lower in February as the company announced the agreement under which Leerink was appointed as the agent to offer and sell its common stock, with a par value of $0.01 per share.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484921262"}